Erastin - CAS:571203-78-6

规格	价格	是否有货	数量
1mg		In-stock
5mg		In-stock
10mg		In-stock

规格

价格

是否有货

数量

1mg

In-stock

5mg

In-stock

10mg

In-stock

Other Forms of Rapamycin:

生物活性

Erastin is a ferroptosis inducer. Erastin binds and inhibits voltage-dependent anion channels (VDAC2/VDAC3).

体外研究

Erastin triggers oxidative, iron-dependent cell death. Treatment of NRAS-mutant HT-1080 fibrosarcoma cells with the RSL molecule erastin (10 µM) results in a time-dependent increase in cytosolic and lipid ROS beginning at 2 hours. Cell death triggered by erastin is significantly inhibited by antioxidants (e.g., α-tocopherol, butylated hydroxytoluene, and β-carotene) and iron chelators, suggesting that ROS- and iron-dependent signaling is required for erastin-induced ferroptosis. Erastin can directly bind to VDAC2/3 in BJeLR cells. Knockdown of VDAC2 and VDAC3, but not VDAC1, leads to erastin resistance. Erastin has the ability to reduce glutathione level by directly inhibiting cystine/glutamate antiporter system Xc− activity, with activation of the ER stress response. Erastin potently inhibits HT-29 cell survival. Erastin shows a dose-dependent effect, and 30 μM of erastin displays the most dramatic effect.

Erastin treatment significantly decreased intracellular GSH levels, indicating the depletion of a hallmark antioxidant of ferroptosis, while concurrently markedly increasing malondialdehyde (MDA) content, a product of lipid peroxidation. Notably, these changes were significantly more pronounced in Lpin3-KO cells than in WT cells, confirming that Erastin effectively triggers the core biochemical reactions of ferroptosis[1].

Western blot analysis further revealed that Erastin treatment substantially upregulated the expression of ACSL4, a positive regulator of ferroptosis, and downregulated the expression of GPX4, a negative regulator. These molecular alterations were also more prominent in Lpin3-KO cells, demonstrating that Erastin precisely targets the ferroptosis-related molecular pathways[1].

体内研究

Intraperitoneal injection of erastin at well-tolerated doses dramatically inhibits HT-29 xenograft growth in severe combined immunodeficient mice.

分子式

C₃₀H₃₁ClN₄O₄

分子量

547.04

CAS号

571203-78-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

溶解性数据

In Vitro:

DMSO : 12.5 mg/mL (22.85 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8280 mL	9.1401 mL	18.2802 mL
5 mM	0.3656 mL	1.8280 mL	3.6560 mL
10 mM	0.1828 mL	0.9140 mL	1.8280 mL

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 50% PEG300 50% saline
Solubility: 5 mg/mL (9.14 mM); Suspended solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.08 mg/mL (3.80 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (3.80 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (3.80 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (3.80 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.25 mg/mL (2.29 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (2.29 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

科研文献

纯度： 98%

Data Sheet

SDS

产品使用指南

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 82 篇科研文献

The molarity calculator equation

The dilution calculator equation